A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 2, 2009, Pages 172.e1-172.e10

  Archer, David F ^a   Seidman, Larry ^b   Constantine, Ginger D ^c   Pickar, James H ^c   Olivier, Sophie ^c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Clinical Research of Philadelphia   (United States)

^c PFIZER INC   (United States)

Author keywords

desvenlafaxine succinate; hot flushes; menopause; nonhormonal treatment; vasomotor symptoms

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSTILITY; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MYDRIASIS; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; VASOMOTOR DISORDER; XEROSTOMIA;

EID: 58749098561     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.09.877     Document Type: Article

References (48)

1. Utian W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 3 (2005) 47-56
2. Cohen L.S., Soares C.N., Vitonis A.F., Otto M.W., and Harlow B.L. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 63 (2006) 385-390
3. Freeman E.W., Sammel M.D., Lin H., and Nelson D.B. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 63 (2006) 375-382
4. Joffe H., Hall J.E., Soares C.N., et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 9 (2002) 392-398
5. Kravitz H.M., Ganz P.A., Bromberger J., Powell L.H., Sutton-Tyrrell K., and Meyer P.M. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 10 (2003) 19-28
6. Woodward S., and Freedman R.R. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep 17 (1994) 497-501
7. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 142 (2005) 1003-1013
8. Gundlah C., Pecins-Thompson M., Schutzer W.E., and Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 63 (1999) 325-339
9. Karkanias G.B., Ansonoff M.A., and Etgen A.M. Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J Neuroendocrinol 8 (1996) 449-455
10. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 57 (2002) 357-384
11. Bachmann G.A. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 50 (2005) 155-165
12. Berendsen H.H.G. The role of serotonin in hot flushes. Maturitas 36 (2000) 155-164
13. Deecher D.C. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 14 (2005) 435-448
14. Deecher D.C., Alfinito P.D., Leventhal L., et al. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 148 (2007) 1376-1383
15. Freedman R.R. Physiology of hot flashes. Am J Hum Biol 13 (2001) 453-464
16. Evans M.L., Pritts E., Vittinghoff E., McClish K., Morgan K.S., and Jaffe R.B. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 105 (2005) 161-166
17. Kimmick G.G., Lovato J., McQuellon R., Robinson E., and Muss H.B. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12 (2006) 114-122
18. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 (2000) 2059-2063
19. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20 (2002) 1578-1583
20. Stearns V., Beebe K.L., Iyengar M., and Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289 (2003) 2827-2834
21. Stearns V., Slack R., Greep N., et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 23 (2005) 6919-6930
22. Nelson H.D., Vesco K.K., Haney E., et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295 (2006) 2057-2071
23. DeMartinis N.A., Yeung P.P., Entsuah R., and Manley A.L. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68 (2007) 677-688
24. Septien-Velez L., Pitrosky B., Padmanabhan S.K., Germain J.-M., and Tourian K.A. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22 (2007) 338-347
25. Liebowitz M., Manley A.L., Padmanabhan S.K., Ganguly R., Tummala R., and Tourian K.A. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 24 (2008) 1877-1890
26. Speroff L., Gass M., Constantine G., Olivier S., and Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 111 (2008) 77-87
27. Goldstein B.J., and Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12 (1998) S55-S87
28. Masand P.S., and Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7 (1999) 69-84
29. Schatzberg A.F., Haddad P., Kaplan E.M., et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 58 Suppl 7 (1997) 5-10
30. European Medicines Agency Committee for Medical Products for Human Use. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women (2005), European Medicines Agency, London, UK
31. US Food and Drug Administration. Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation (2003), US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Rockville, MD
32. McNair D.M., Lorr L., and Droppleman L.F. EDITS manual for the profile of mood states (1992), Educational and Industrial Testing Service, San Diego
33. DeLoach L.J., Higgins M.S., Caplan A.B., and Stiff J.L. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 86 (1998) 102-106
34. Greene J.G. Constructing a standard climacteric scale. Maturitas 29 (1998) 25-31
35. Hill C.D., Fehnel S.E., Bobula J.D., Yu H., and McLeod L.D. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 14 (2007) 1047-1055
36. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-809
37. Maclennan A.H., Broadbent J.L., Lester S., and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev (2004) CD002978.
38. Cassano P., and Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 16 (2004) 15-25
39. Clayton A.H., Pradko J.F., Croft H.A., et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63 (2002) 357-366
40. Fava M., Amsterdam J.D., Deltito J.A., Salzman C., Schwaller M., and Dunner D.L. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 10 (1998) 145-150
41. Fava M. Weight gain and antidepressants. J Clin Psychiatry 61 Suppl 11 (2000) 37-41
42. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., and Khan Z.M. Antidepressant-induced sexual dysfunction. Ann Pharmacother 36 (2002) 1577-1589
43. Harrison C.L., Ferrier N., and Young A.H. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol 18 (2004) 200-204
44. Montejo-Gonzalez A.L., Llorca G., Izquierdo J.A., et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23 (1997) 176-194
45. Cymbalta. [package insert] (2005), Eli Lilly and Co, Indianapolis, IN
46. Effexor XR. [package insert] (2006), Wyeth Pharmaceuticals Inc, Collegeville, PA
47. Haddad P.M. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Saf 24 (2001) 183-197
48. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clin Ther 25 (2003) 2138-2154